Fig. 1 · Structure
Documents & Downloads
Bafrekalant
Active Compound
Bafrekalant is a diazabicyclic substituted imidazo[l,2-a]pyrimidine derivative that acts as a modulator of respiratory function. It shows potential for the investigation of breathing disorders, including obstructive and central sleep apnea, as well as snoring. Bafrekalant may serve as a valuable tool for researchers studying the mechanisms underlying these conditions and developing therapeutic interventions.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Modulator |
| CAS Number | 2256770-44-0 |
| Applications | Active Compound |
| Formula | C29H31ClN6O2 |
| Molecular Weight | 531.05 |
| SMILES | CC(C1=CC=C(C=C1)C2=C(N(C=CC=N3)C3=N2)CN(CC4CC5)CC5N4C(C(N=C6OC)=C(C=C6)Cl)=O)C |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.